Search

Search Constraints

You searched for: Author/Creator Kosiborod, Mikhail N.

Search Results

1. A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF). (21st March 2019)

2. All‐cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK. Issue 1 (26th September 2022)

3. Association Between Change in Ambulatory Hemodynamic Pressures and Symptoms of Heart Failure. (November 2021)

4. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF. (24th November 2021)

5. Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled Trial. Issue 5 (May 2022)

6. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Issue 20 (18th May 2021)

7. Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE‐HF trial. Issue 6 (26th March 2021)

8. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. (9th June 2021)

9. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. (7th November 2022)

10. Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF. (6th February 2022)